Linked from

The 10 pages that link to Isoniazid, each with the reason it gives.

• Drug metabolismBroader topic: Inherited acetylation differences affect its persistence and adverse-effect risks.

• Drug-induced liver injuryBroader topic: Its injury risk illustrates the roles of dose, metabolism, and host susceptibility.

• StreptomycinCompared with: Unlike streptomycin, it targets mycobacterial cell-wall construction.

• RifampicinCompared with: It targets the mycobacterial cell wall rather than RNA polymerase.

• Mycolic acidRelated: Its activity disrupts the production of a key envelope component.

• Multidrug-resistant tuberculosisRelated: Resistance to this drug is one required feature of the MDR-TB definition.

• Pyridoxal phosphateRelated: Isoniazid can reduce functional PLP availability, making pyridoxine supplementation relevant in some patients.

• EthambutolCompared with: It targets a different cell-envelope pathway and is paired with ethambutol in initial treatment.

• PyrazinamideRelated: It is commonly paired with pyrazinamide during the initial phase of treatment.

• 4-Aminosalicylic acidCompared with: Isoniazid became a more potent standard treatment, narrowing PAS’s routine role.